

BY E-MAIL

November 24, 2021

BSE Ltd. Phiroze Jeejeebhoy Towers 27 th Floor, Dalal Street Mumbai 400 023 E-mail: corp.relations@bseindia.com	The National Stock Exchange of India Ltd. Exchange Plaza, 5 th Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051. E-mail : takeover@nse.co.in
--	--

Dear Sir,


Re: Declaration under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith disclosure for acquisition of 76,24,142 equity shares of Rs. 10/- each of M/s. Lyka Labs Limited constituting 26.574% voting rights of the said Company.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For and on behalf Ipca Laboratories Limited



Harish P. Kamath
Company Secretary

Encl: a/a

Cc: Lyka Labs Ltd.
4801/B & 4802/A, GIDC Industrial Estate,
Ankleshwar – 393 002, Gujarat
E-mail id : companysecretary@lykalabs.com

Ipca Laboratories Ltd.
www.ipca.com

Format for disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Part A – Details of Acquisition

Name of the Target Company (TC)	Lyka Labs Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Ipca Laboratories Limited		
Whether the acquirer belongs to Promoter / Promoter Group	No.		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights	3,37,586	1.18%	1.18%
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	3,37,586	1.18%	1.18%
Details of Acquisition / Sale			
a. Shares carrying voting rights acquired	76,24,142	26.57%	26.57%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	76,24,142	26.57%	26.57%



Ipca Laboratories Ltd.
www.ipca.com

After the acquisition, holding of			
a. Shares carrying voting rights	79,61,728	27.75%	27.75%
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
f. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
d. Total (a+b+c+d)	79,61,728	27.75%	27.75%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Open Market Purchase		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	Not Applicable this being open market purchase		
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	22 nd to 24 th November, 2021 (Disclosure Trigger limit reached on 23 rd November, 2021)		
Equity share capital/total voting capital of the TC before the said acquisition	2,86,90,000	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	2,86,90,000	100%	100%
Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants)	2,86,90,000	100%	100%

M. Anand